news_6

IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--#Biopharmaceutical--IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of...